International Journal of Epidemiology, 2018, 1355 doi: 10.1093/ije/dyy083 Advance Access Publication Date: 7 May 2018 Letters to the Editor Letters to the Editor Alain Braillon Department of Medicine, University Hospital, 80000, Amiens, France. E-mail: email@example.com Taylor et al. must be commended for their observational is too rarely implemented. It allows the patient to easily study in the general practice setting, showing that long- implement the dose–response principle and to cope with term smoking cessation was more frequent with vareni- craving. cline than with nicotine replacement therapy (NRT): 29% Third, could Taylor et al. provide data about motiva- vs 24% at 2 years (odds ratio, 1.3). Indeed, too few data tional interviewing and psychological support? Cigarette are available in the real-life setting, as well as in the long smoking is one of the worst addictions and most smokers term. However, this work warranted some comments. have experienced several painful and desperate failures. First, the Clinical Practice Research Datalink, a They need to be cared for with reassurance, information not-for-profit research service funded by the NHS National provision and motivation. Psychological support is a key 3,4 Institute for Health Research and the Medicines and issue for smoking cessation. Healthcare products Regulatory Agency, is a most unique achievement. Accordingly, participating practitioners may References be among the best professionals, even more so as they 1. Taylor GMJ, Taylor AE, Thomas KH et al. The effectiveness of receive regular practice-level prescribing and patient safety varenicline versus nicotine replacement therapy on long-term reports, including patient case-finding and national practice smoking cessation in primary care: a prospective cohort study of benchmarking. This could explain the high rate of smoking electronic medical records. Int J Epidemiol 2017;46:1948–57. cessation recorded. Could Taylor et al. provide the percent- 2. Stead LF, Perera R, Bullen C et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev age of general practitioners in England participating in the 2012;11:CD000146. Datalink? 3. Leas EC, Pierce JP, Benmarhnia T et al. Effectiveness of pharma- Second, only 23% of the patients prescribed NRT were ceutical smoking cessation aids in a nationally representative prescribed more than one nicotine product. This could cohort of American smokers. J Natl Cancer Inst 2018;6:581–7. explain the difference compared with varenicline: the ‘belt 4. Apollonio D, Glantz SA. Tobacco industry research on nicotine and braces’ strategy (patches combined with faster acting for- replacement therapy: “If anyone is going to take away our busi- ms—lozenge or spray) doubles the odds ratio of quitting but ness it should be us”. Am J Public Health 2017;107:1636–42. V The Author(s) 2018; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association 1355
International Journal of Epidemiology – Oxford University Press
Published: Aug 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera